Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$27.64 USD
-0.62 (-2.19%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $27.65 +0.01 (0.04%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.64 USD
-0.62 (-2.19%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $27.65 +0.01 (0.04%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Zacks News
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
by Zacks Equity Research
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
by Zacks Equity Research
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
by Sundeep Ganoria
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
by Zacks Equity Research
Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 135.9% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ligand (LGND) Beats on Q3 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.
Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 119.2% in Verona Pharma PLC American Depositary Share (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verona Pharma PLC American Depositary Share (VRNA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $20.91, moving +0.34% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Verona Pharma PLC American Depositary Share (VRNA) closed at $20.06, marking a -1.43% move from the previous day.
Verona Pharma PLC American Depositary Share (VRNA) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $19.51, moving -0.46% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $18.85 in the latest trading session, marking a -0.05% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $21.78, moving +1.59% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $21.43 in the latest trading session, marking a +0.4% move from the prior day.
Verona (VRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $22.50, moving +0.72% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $22.05, moving -1.21% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $20.50 in the latest trading session, marking a -1.44% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $22.53 in the latest trading session, marking a -0.75% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $23.69 in the latest trading session, marking a -0.96% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $23.76 in the latest trading session, marking a -1% move from the prior day.
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences
by Zacks Equity Research
AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.